^
Association details:
| Biomarker: | AXL Y821 |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A128 - AXL Mediates Cetuximab Resistance Through Tyrosine 821 and Activation of c-Abl kinase in Head and Neck Cancer View Presentation Add to Schedule
Published date:
10/27/2019
Excerpt:
Advancing this line of investigation in vivo indicated that tumors overexpressing AXL were resistant to cetuximab whereas tumors harboring the Y821 mutation were sensitive.
